Grant: Project Grant - Priority Announcement: Early Detection/Cancer Prevention
McMaster University
$100,000.00
Targeting BACE1 for the prevention and treatment of Brain metastases
FY 2023-24
Summary
Brain metastases (BM) are brain tumors arising from primary cancer cells from different organs in the body that escape and travel to the brain. Lung cancer, the most common cause of cancer-related deaths in adults is the most common cause of BM. As therapies for the treatment of primary cancers are becoming more effective at controlling a patient's primary disease, they are ironically dying from metastatic disease to the brain, therefore the ability to prophylactically prevent the formation of BM altogether can be a game-changer for cancer patients. Using the genome-editing technology CRISPR, we screened for genes whose increased expression would increase the spread of lung cancer to the brain. We found that increased expression of Beta secretase 1 (BACE1) facilitated the spread of lung cancer cells to the brain. We found that increased expression of BACE1 enhanced activation of the epidermal growth factor receptor (EGFR), a major player in lung cancer, where activating mutations lead to increased likelihood of developing BM. We hypothesize that BACE1 directly cleaves EGFR to activate a metastatic program to facilitate lung cancer BM and therapeutically targeting BACE1 will reduce the growth/formation of BM. We will perform proteomic screens to identify the cleavage site in EGFR as well as binding partners of BACE1. We will then test whether inhibition of BACE1 with existing brain penetrant compounds will prevent the formation of BM. Lastly, because existing inhibitors are not specific for BACE1 over BACE2, we will develop a novel, brain penetrant BACE1 inhibitor in collaboration with medicinal chemist Dr. Jake Magolan at McMaster University. We envision that this approach will lead to rapid translation of novel drugs into clinical trials to improve patient survival.
Department
Program
Project Grant - Priority Announcement: Early Detection/Cancer Prevention
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
494957
Name
Singh Sheila K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Targeting BACE1 for the prevention and treatment of Brain metastases
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Early Detection/Cancer Prevention
Keyworddelim
Bace-1 Inhibitors; Beta Secretase-1 (Bace1); Brain Metastases Preclinical Models; Drug Development; Egfr; Lung To Brain Metastases; Patient-Derived Xenograft Models
Abstract
Brain metastases (BM) are brain tumors arising from primary cancer cells from different organs in the body that escape and travel to the brain. Lung cancer, the most common cause of cancer-related deaths in adults is the most common cause of BM. As therapies for the treatment of primary cancers are becoming more effective at controlling a patient's primary disease, they are ironically dying from metastatic disease to the brain, therefore the ability to prophylactically prevent the formation of BM altogether can be a game-changer for cancer patients. Using the genome-editing technology CRISPR, we screened for genes whose increased expression would increase the spread of lung cancer to the brain. We found that increased expression of Beta secretase 1 (BACE1) facilitated the spread of lung cancer cells to the brain. We found that increased expression of BACE1 enhanced activation of the epidermal growth factor receptor (EGFR), a major player in lung cancer, where activating mutations lead to increased likelihood of developing BM. We hypothesize that BACE1 directly cleaves EGFR to activate a metastatic program to facilitate lung cancer BM and therapeutically targeting BACE1 will reduce the growth/formation of BM. We will perform proteomic screens to identify the cleavage site in EGFR as well as binding partners of BACE1. We will then test whether inhibition of BACE1 with existing brain penetrant compounds will prevent the formation of BM. Lastly, because existing inhibitors are not specific for BACE1 over BACE2, we will develop a novel, brain penetrant BACE1 inhibitor in collaboration with medicinal chemist Dr. Jake Magolan at McMaster University. We envision that this approach will lead to rapid translation of novel drugs into clinical trials to improve patient survival.
Competitiondate
202309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Singh, Sheila K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~